Catalyst Wire Dossier Catalyst Wire Dossier

Recombinant H3N2 influenza strain A/Texas/71/2017 (H3N2, Clade 3C3a)

· National Institute of Allergy and Infectious Diseases (NIAID)
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Recombinant H3N2 influenza strain A/Texas/71/2017 (H3N2, Clade 3C3a), covering 2023-11-30 to 2023-11-30. Get the full timeline:

Most recent: Clinical Trial Update: Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain [Phase 1]

See pricing